If we were to move toward a pharmacare program, I think the point I wish to make here is that oftentimes with a pharmacare program we end up using generic drugs because they tend to be cheaper. That's where governments tend to invest their money.
However, I think the point needs to be noted that often they're not as effective as other drugs. This means we are putting patients in a scenario where, yes, some of their drugs are going to be covered by a public plan, but they are still going to have to pay out-of-pocket when those generics are not effectively useful for them.
I'm not looking for a comment on that; I'm actually looking to let my statement stand.
My next question here would be with regard to BIOTECanada. I'd like you to comment on whether or not a pharmacare program would, in fact, advance innovation with regard to your industry.